Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 201

The DOI matches its OpenAlex record.

Phase II Study of Oral Capecitabine in Patients With Advanced or Metastatic Pancreatic Cancer

Thomas H. Cartwright, Allen Lee Cohn, Jerry A. Varkey, Yin-Miao Chen, Ted P. Szatrowski, John Vernon Cox, Joseph J. Schulz·2002·Journal of Clinical Oncology

Abstract

PURPOSE: To determine the safety and efficacy of capecitabine (Xeloda; Roche Laboratories, Nutley, NJ) in patients with metastatic or unresectable, locally advanced pancreatic cancer. PATIENTS AND METHODS: Forty-two patients were treated with oral capecitabine 1,250 mg/m(2) administered twice daily (2,500 mg/m(2)/d) as intermittent therapy in 3-week cycles consisting of 2 weeks of treatment followed by 1 week without treatment. Tumor lesions were assessed by computed tomography scan or physical examination at 6-week intervals (after every two cycles). Adverse events were monitored continuously during treatment and for 28 days after the last dose of study drug. RESULTS: Ten (24%) of 42 patients experienced a clinical benefit response (95% confidence interval [CI], 12.1% to 39.5%) as evidenced by improvement in pain intensity, analgesic consumption, and/or Karnofsky performance status. Three (7.3%) of the 41 patients with measurable disease had an objective response (partial). The median time to objective response was 85 days (range, 47 to 91 days) and duration of response was 208, 260, and 566 days for the three responding patients. One patient with nonmeasurable but assessable disease had improved residual disease with a positive clinical benefit response, for a total of four responses among the 42 assessable patients, for an overall response rate of 9.5% (90% CI, 3.3% to 20.5%). Capecitabine was generally well tolerated. CONCLUSION: Treatment with capecitabine resulted in clinically significant beneficial effects on tumor-related symptoms and yielded objective response activity in patients with metastatic or locally advanced pancreatic cancer. These results together with its generally tolerable safety profile and the added advantage of oral administration provide the basis for further evaluating capecitabine as a single agent or in combination with other treatment modalities in this patient population.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

OpenAlex · 10.1200/jco.20.1.160

Cites

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cited by

See all 201

Metadata

Authors
Cartwright, T. H., Cohn, A. L., Varkey, J. A., Chen, Y.-M., Szatrowski, T. P., Cox, J. V., & Schulz, J. J.
Venue
Journal of Clinical Oncology
Publisher
Lippincott Williams & Wilkins
Published
2002-01-01
Volume
20
Issue
1
Pages
160-164
ISSN
0732-183X (ISSN-L)
OpenAlex
W2128259734
Cited by
201
References
0
FWCI
7.13
Type
journal article
Language
en
Open access
closed

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Phase II Study of Oral Capecitabine in Patients With Advanced or Metastatic Pancreatic Cancer. https://app.cochat.ai/papers/10.1200/jco.20.1.160
The paper
Cartwright, T. H., Cohn, A. L., Varkey, J. A., Chen, Y.-M., Szatrowski, T. P., Cox, J. V., & Schulz, J. J. (2002). Phase II Study of Oral Capecitabine in Patients With Advanced or Metastatic Pancreatic Cancer. Journal of Clinical Oncology. https://doi.org/10.1200/jco.20.1.160

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.